An editorial by Robert Howard in the BMJ (2024;386:q2044) entitled "Lecanemab's benefits are too small and uncertain" argues that the benefits of lecanemab are insufficient. The author was an unpaid member of the scientific board of Synaptogenix, which was added to the statement of competing interests.[1] Studies have shown that after 18 months of treatment with lecanemab, cognitive decline was slowed by 27% according to the CDR-SB scale in patients with early Alzheimer's disease.[1][2][7] CDR-SB scores increased by 1.21 in treated versus 1.66 in placebo.[1] Adverse events included infusion reactions in 15% of patients (vs. 6% placebo) and microhemorrhages in 2% (vs. 1% placebo).[1] Most cases of ARIA have been mild or asymptomatic, but serious complications have occurred in practice, including massive brain hemorrhage requiring hospitalization.[1]